I think this is a very important slide from the last trial results presentation, showing that control patients who received dexamethasone showed no survival benefit. But once treated with Remestemcel-L + dexamethasone, a significant survival benefit of 75% at day 60 and 77% at day 90 was observed (in patients<65).
No treatment for ARDS has ever shown such a significant mortality reduction in any patient population. These are the sickest Covid-19 patients who are in ICU on mechanical ventilation who now have an 86% chance of survival compared to just 55% with current SOC.
I think this is a very important slide from the last trial...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.040(3.88%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.265M | 4.929M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 95953 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2244 | 4 |
View Market Depth
| Last trade - 15.44pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |